Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

tems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimburs
'/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... , , , ... (PMO) in Ohio and more than 900,000(3) are at risk for the ... the number of women suffering from the disease is predicted to increase ... predicted increase, a national Harris Interactive survey commissioned by the Know ...
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
Cached Medicine Technology:Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 2Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 3Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 4Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 5Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 6Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 7Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 8Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease 9Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... NEW YORK, SEATLLE, GAINESVILLE, Fla. and SUNNYVALE, Calif., ... quality of care for Parkinson,s patients, the National ... physicians, physician assistants, nurses, physical therapists, speech-language pathologists, ... teach the latest methods of Parkinson diagnosis and ...
... from bone marrow may serve as a novel therapeutic option ... characterized by extraordinarily fragile skin, according to a study pre-published ... American Society of Hematology. , , ... fragile skin and blistering on touch, akin to third degree ...
... Although there are many issues,facing Americans throughout the country ... Holiday Season is always viewed as a joyous time to ... even more difficult for,those people who have experienced the death ... this year, may now echo with greater,sadness, emptiness and loss. ...
... Pittsburgh-based Foundation Radiology,Group (FRG) was named by the Radiology Business ... the country. Located in Gateway Center in downtown,Pittsburgh, FRG has ... get,recognized by industry leaders and national experts. , ... of being in operation, FRG was ranked 44th out of,50 ...
... Health Insurer Brings More Jobs to Lodi , ... forward with its long-term commitment to the Lodi community, Blue ... Lodi customer service center today with a ribbon-cutting ceremony at ... families from 5:00 - 7:00 p.m. The new facility ...
... Bermuda, Dec. 4 The Board of Directors of Tyco International Ltd. ... cash dividend of $0.20 per common share. The dividend is payable ... 2009. , , ABOUT TYCO ... is a diversified, global company that provides vital products and services to ...
Cached Medicine News:Health News:Allied Team Training For Parkinson 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:In-House Hospice Offers Help to Those Living With Grief During Holiday Time 2Health News:Foundation Radiology Group Named One of 50 Largest Radiology Groups in the Country 2Health News:Blue Shield of California Celebrates Completion of New Lodi Campus 2Health News:Blue Shield of California Celebrates Completion of New Lodi Campus 3
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: